BackJanux Therapeutics Overview
Janux Therapeutics Inc

Janux Therapeutics Target Price

Analysts' average 12-month price target for Janux Therapeutics is $33.

Get informed when a big investor buys or sells

+ Follow

Share Price

$18.03

Average Target Price

$32.8382.1% upside

6 analysts in the last 4 months

High: $55 | Low: $22

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-24Wolfe Research$2327.6% upsideOpen
2026-08-07Stifel Nicolaus$3594.1% upsideOpen
2026-08-07Guggenheim$55205% upsideOpen
2026-06-25Truist Financial$2644.2% upsideOpen
2026-05-11Evercore ISI$2222% upsideOpen
2026-05-08Wedbush$3699.7% upsideOpen
2026-04-20BarclaysEtzer Darout$1422.4% downsideOpen
2026-04-15UBS$1516.8% downsideOpen
2026-01-16Piper SandlerKelsey Goodwin$3066.4% upsideOpen
2025-12-17Barclays$2960.8% upsideOpen
2025-12-02UBSDavid Dai$57216.1% upsideOpen
2025-12-02Stifel NicolausStephen Willey$38110.8% upsideOpen
2025-12-02H.C. Wainwright$45149.6% upsideOpen
2025-09-16Barclays$47160.7% upsideOpen
2025-09-10Stifel Nicolaus$45149.6% upsideOpen
2025-09-03GuggenheimBrad Canino$72299.3% upsideOpen
2025-07-11Raymond JamesSean McCutcheon$65260.5% upsideOpen
2025-02-28Scotiabank$41127.4% upsideOpen
2025-02-28Wedbush$76321.5% upsideOpen
2024-12-03BTIGJustin Zelin$100454.6% upsideOpen
2024-10-24UBSDavid Dai$69282.7% upsideOpen
2024-09-05Stifel NicolausBradley Canino$70288.2% upsideOpen
2024-08-09ScotiabankGeorge Farmer$42132.9% upsideOpen
2024-05-30ScotiabankGeorge Farmer$47160.7% upsideOpen
2024-05-13H.C. WainwrightSwayampakula Ramakanth$63249.4% upsideOpen
2024-03-20BTIGKaveri Pohlman$62243.9% upsideOpen

Janux Therapeutics (JANX) FAQ

Janux Therapeutics's target price stands at $33. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

The Street's average target of $33 for JANX implies 82.1% upside versus today's price ($18.03). Positive implied upside usually reflects optimism on growth or margins, while a large downside can signal valuation or fundamental concerns. Check recommendation mix and recent target changes for more context.

The history chart shows how Janux Therapeutics's target price evolved across reporting periods, while the comparison chart places JANX next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, target price is commonly used to spot outliers. Janux Therapeutics's reading of $33 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.